This study addresses three important aspects of ACC biology: (a) generation of an in vitro model to study the significance of MYB, (b) validation of BUB1 as a target gene of MYB, (c) the potential use of BUB1 inhibition as a therapeutic strategy. This evidence concerns the gene MYB and adrenal cortex carcinoma.